Ghrelin and insulin secretion in humans: not a tale of two hormones?

Failure of pancreatic b-cells to secrete adequate amounts of insulin is a fundamental defect in type 1 and type 2 diabetes, and the search for innovative strategies to improve b-cell mass and function is a major priority in diabetes research. Ghrelin, a 28-amino acid peptide hormone predominantly secreted by the stomach, was identified as ligand of the growth hormone secretagogue receptor type-1a (GHSR-1a) (1). The Ser3-octanoylated ghrelin form (acylated ghrelin [AG]) also was soon recognized to act as a hypothalamic orexigenic signal (2) and to modulate tissue pathways and functions as a potential contributor to metabolic adaptation to low nutrient availability. Experimental AG administration commonly causes weight gain and hyperglycemia by enhancing food intake, fat deposition, and hepatic gluconeogenesis (3–5). A more comprehensive understanding of the metabolic impact of ghrelin has been recently allowed by the increasing appreciation of the independent, and generally more favorable, effects of its unacylated form (UAG), which does not increase food intake or circulating glucose in vivo (3,4,6). Although no specific UAG receptor has been yet identified, UAG coadministration may counteract the glucogenic effects of AG as well as AG-induced hyperglycemia (3,4,7), and positive or negative associations have been respectively reported in humans between AG or UAG and markers of whole-body insulin resistance (8). Modulating the AG–UAG balance by inhibiting the acylating enzyme ghrelin O-acyltransferase (9) or by exogenous hormone administration has therefore become an attractive therapeutic target to limit positive energy balance and altered glucose metabolism in obese and insulinresistant states. Importantly, both AG and UAG also contribute to regulate b-cell function and insulin secretion (10). GHSR-1a was identified in b-cells, and ghrelin expression has been described in different cell types in pancreatic islets (11). These observations introduce the concept that ghrelin is involved in a paracrine network regulating insulin release, although local hormone concentrations and interactions between systemic and pancreatic ghrelin remain poorly defined. GHSR-1a signaling may negatively modulate cAMPand calcium-dependent glucose–stimulated insulin release (12). Indirect AG effects, including negative regulation of vagal stimulation (13), could result in additional inhibition of insulin secretion. Therefore, AG has been commonly considered an insulinostatic hormone, although it should be pointed out that reports of AG-stimulated insulin secretion are also available from experimental models (10), likely due to differences in cell lines, animal species, and hormone concentrations (10,12). Studies in humans are notably less controversial, and most of them indicate that circulating insulin is acutely reduced following bolus or continuous AG infusion (7,14,15), also at near-physiologic levels (15). On the other hand, available information indicates that UAG may counteract the negative effects of AG or directly enhance insulin secretion in vitro and in animal models (7,16,17). In healthy individuals, UAG acutely prevented the AG-induced insulin decline (7), and overnight UAG infusion transiently increased postprandial insulin (18). A comprehensive assessment of the potential positive impact of UAG in the regulation of insulin secretion is therefore of major clinical interest for treatment of declining insulin secretion in insulin resistance and diabetes. In the current issue, Tong et al. (19) investigated the effects of bolus followed by continuous, 210-min intravenous infusions of pharmacologic AG and UAG doses (1 and 4 mg/kg/h, respectively) on circulating insulin in healthy volunteers under fasting and intravenous glucosestimulated conditions. The key findings of the study are negative, as the inhibitory effect of AG on plasma insulin following intravenous glucose was unaffected by concomitant UAG infusion. UAG was also unable to modulate the negative impact of AG on intravenous glucose tolerance,